Intralesional cryotherapy with triamcinolone and onabotulinumtoxinA injections for umbilical keloid: A case report

Jennifer VH Tran, Shantel DJ Lultschik, Sheetal Sapra, Kevin Dong, Klaudija Gusic and Matthew Goldstein

Abstract

Introduction: Keloid scars are therapeutically challenging and although many treatment options exist, there are no specific guidelines, and few reports have discussed keloids in the umbilical region.

Methods: Here, we present a successful treatment of a 31-year-old female with a history of a recurrent keloid in the umbilical region. The keloid was treated using intralesional cryotherapy followed by intralesional onabotulinumtoxinA and triamcinolone acetonide injections.

Discussion: The patient expressed high satisfaction, minimal side effects, and no recurrence.

Conclusion: Overall, due to the low rate of side effects, high patient satisfaction, and absence of recurrence, this treatment modality should be considered as an option for umbilical keloids.

Keywords

Umbilical, keloid, scar, intralesional, cryotherapy, cryoShape, botulinum toxin, triamcinolone acetonide

Lay Summary

Background to subject: Keloids are a type of scar that are difficult to treat. There are many treatment options available, but there is no single best treatment for keloids that form around the belly button region.

Question being asked: Is intralesional cryotherapy with intralesional onabotulinumtoxinA and triamcinolone acetonide injections effective at treating keloids in the belly button region? How the work was conducted: We treated a 31-year-old female with a keloid around the belly button region that returned after prior treatment. The keloid was treated using combination therapy of freezing the keloid from the inside out, which is called intralesional cryotherapy. This was followed by two types of injections, called onabotulinumtoxinA and triamcinolone acetonide, directly into the keloid. What we learned: Overall, due to the low rate of side effects, high patient satisfaction and the keloid not returning, this treatment plan should be considered as an option for keloids in the belly button region. What we did not learn: This treatment may or may not be effective and safe for all patients of all skin types and demographics as this treatment was performed for only one patient.
Introduction

Keloids are fibrous overgrowths that occur following trauma to the skin. Common causes include burns, acne, piercings, surgical procedures, and vaccinations. The formation of keloids is around 15 times more likely for those with darker pigmentation. In addition to cosmetic concerns, patients can experience pain and pruritus. As a result, keloids can have physical, psychological, and social consequences. Umbilical keloids are becoming more prevalent with the increase in laparoscopic surgery and piercings; however, they can be more complex to treat since there is an increased chance of producing inclusion cysts that can become infected. Although many treatment strategies exist, there have been few studies investigating umbilical keloids and treatment remains challenging due to lack of specific guidelines as well as high recurrence rates and variability in outcomes. This case study reports a complete resolution of a pedunculated umbilical keloid, treated with intralesional cryotherapy followed by IL triamcinolone acetonide and onabotulinumtoxinA injections.

Case report

A 31-year-old woman of Fitzpatrick skin type IV presented with an over two-year history of a large 2 cm thick pedunculated keloid located in the umbilical region following a piercing (Figure 1). The patient’s mother was known to develop keloids. Past medical history revealed that the keloid was surgically excised two years prior followed by IL triamcinolone acetonide injections; however, the keloid grew back to twice the original size. Detailed information regarding the previous treatment of the umbilical keloid is not available as it was completed at a different clinic. The patient did not recall the timing or number of sessions of IL triamcinolone acetonide injections. The recommended treatment for this patient included IL cryotherapy (CryoShape™; Etgar Group International Ltd, Kfar Saba, Israel) followed by IL triamcinolone acetonide and onabotulinumtoxinA injections (Botox® Cosmetic; Allergan Inc., Markham, Canada). However, this treatment is contraindicated if an umbilical hernia is present due to potential adverse consequence of damage to the underlying bowels. Therefore, prior to determining a treatment plan for the keloid, the treating clinician should perform a thorough physical examination and review of the patient’s medical history to exclude the presence of a hernia. An ultrasound scan is recommended if there is any suspicion of a hernia. If an umbilical hernia is present, the patient should be referred to a general surgeon for hernia management prior to keloid treatment.

The patient provided written consent to the publication of patient information and images. The patient took acetaminophen 500 mg tablet one-hour prior to the procedure and one-hour post-procedure for pain management. On the day of the procedure, the patient was given 25 cc consisting of lidocaine 2% and bupivacaine hydrochloride 0.5%. A disposable single-use cryoprobe was inserted through the keloid (Figure 2). The proximal part of the probe was connected via an elongation tube to the cryogun, which when activated allowed the cryogen to enter the cryoneedle. The cryoneedle was withdrawn after 34 mins when complete freezing of the keloid was achieved. A complete freezing is achieved when the keloid and 0.5–1.0 cm of the surrounding skin is indurated and frozen. The entire process generally takes between 5 to 60 mins. Post-procedure, the patient was prescribed codeine/acetaminophen...
30 mg/300 mg 1–2 tablets every four hours as needed for pain management. Docusate sodium 50 mg 1–2 tablets twice daily was prescribed alongside the codeine/acetaminophen to counteract opioid-induced constipation. Sodium fusidate 2% topical was provided for the patient to apply twice daily for 14 days for infection prophylaxis. The patient was asked to send photos documenting the keloid healing process during the first month post-procedure (Figures 3 and 4). Desonide ointment 0.05% was prescribed for inflammation noted by the clinician in patient-provided photographs 18 days post-procedure to be used daily for 10 days then every third day. The patient was seen for a follow-up 28 days post-procedure (Figure 5).

After 63 days post-procedure, the patient started using a twice daily topical treatment consisting of niacinamide, tranexamic acid, 1,4-diaminobutane dihydrochloride, bisabolol and kojic acid for hyperpigmentation and hypertrophic scarring (Figure 6). The patient reported being very happy with the results. After 104 days post-procedure, the patient had mild keloid reformation and started injections of 40 mg IL triamcinolone acetonide and 5–10 units of onabotulinumtoxinA (Figure 7). The patient received this same treatment three times with an average of 39 days between treatments. After 223 days post-procedure, the concentration of triamcinolone acetonide was decreased to 10 mg due to the reduction in size of the keloid (Figure 8). The patient was satisfied with the response and elected to stop treatment 273 days post-procedure as she was pregnant. The patient tolerated treatments well and did not report pain during treatments. The patient experienced post-procedural pain, which was alleviated with codeine/acetaminophen 30 mg/300 mg as needed. The total length of follow-up was 273 days since the IL cryotherapy procedure or 50 days post-IL injections. The patient was informed to contact the clinic if any sign of recurrence appears. After 864 days post-IL cryotherapy, at the time the case was reviewed, there had been no further contact with the patient.
Discussion
Keloids have several well-studied treatment options such as occlusive dressings, compressive therapy, topical imiquimod, topical mitomycin C, IL and topical 5-fluorouracil, interferons, bleomycin, surgical techniques, cryotherapy, radiation therapy, pulsed-dye laser, ablative laser, laser-assisted drug delivery, platelet-rich plasma, and IL steroids.\(^8\) IL steroids, in particular triamcinolone acetonide, serve as first-line treatment options for keloids. IL triamcinolone acetonide as a monotherapy has reduced keloid recurrence to an average of 50 percent after surgical excision.\(^9\)–\(^12\) Corticosteroids suppress inflammation and mitosis as well as increasing vasoconstriction within the scar.\(^13\) The effects and efficacy of IL onabotulinumtoxinA for keloid resolution are not as well-known due to lack of clinical trials or case reports; however, studies support the role of botulinum toxin for scar management through modulation of fibroblast activity and alleviation of muscular tension.\(^14\) Through paralyzing the neighbouring muscle mass, botulinum toxin reduces the tensile forces involved in the wound healing process, which can decrease the inflammatory response involved in scar hypertrophy and keloid formation.\(^15\) Botulinum toxin also decreases levels of transforming growth factor β1 and connective tissue growth factor causing inhibition of fibroblast overproliferation of the keloid, modulating fibroblast cell cycle, changing the expression of genes involved in keloidogenesis, and preventing fibroblast-to-myofibroblast differentiation.\(^14\) A six month double-blinded comparative study evaluating the effects of IL botulinum toxin versus IL corticosteroid therapy on keloid scars showed that there were non-significant differences between results; however, IL botulinum toxin showed greater improvement in itchiness, pain, tenderness, patient satisfaction, and no post-study side effects in comparison to IL corticosteroids.\(^16\)

Other clinical trials have shown that the results of keloid resolution of IL corticosteroids versus combination of IL botulinum toxin and corticosteroid is minimal; however, the latter has higher tolerance, aesthetic results, and patient satisfaction.

Contact liquid nitrogen or cryotherapy, which is applied directly to the skin, has been effective at treating keloids;\(^17\) however, this method has been associated with multiple side effects, such as hypopigmentation, blistering, swelling, and infection.\(^18\) Although management of keloids using contact cryotherapy has led to significant improvement or complete regression of keloids, it can require up to 20 treatments.\(^18\)\(^,\)\(^19\) Due to these limitations of contact cryotherapy, IL cryotherapy has been recently recognized as a more effective method to treat keloids.\(^20\)

IL cryotherapy targets the deeper aspect of the keloid and spares the surface epithelium, which reduces the incidence of blistering, hypopigmentation, and other surface reactions.\(^20\)\(^,\)\(^21\) Additionally, IL cryotherapy maximizes keloid freezing compared to contact cryotherapy, enhancing volume decrease as new scar tissue forms without keloidal characteristics.\(^21\) IL cryotherapy effectively destroys a keloid through two types of injuries: physical and vascular. Rapid freezing results in direct irreversible cellular injury and cell dehydration due to production of intracellular ice crystals. Damage and failure of microcirculation results in endothelial cell injury due to vascular stasis.\(^21\) Freezing the keloid prevents recurrence through the absence of scar-inducing wound contractions and differentiation towards a normal non-scarring fibroblast phenotype.\(^21\) There are multiple studies...
illustrating IL cryotherapy as a superior treatment to contact cryotherapy due to improved efficacy and safety while requiring fewer treatments.\textsuperscript{17,20–23} Overall, these studies show IL cryotherapy to be an efficacious treatment with acceptable side effects and recurrence rates.\textsuperscript{23–26}

We encountered a large keloid in the umbilical region that was effectively minimized through IL cryotherapy treatment followed by IL triamcinolone acetonide and onabotulinumtoxinA injections. The patient was predisposed to keloids as the patient is of Fitzpatrick skin type IV and has familial history of keloids. This case is in line with studies showing genetics and ethnicity play a factor as individuals with darker skin pigmentation are at a greater risk of development of keloids.\textsuperscript{27} Keloid formations in the umbilical region are rarely discussed; there have been multiple studies and case reports, however, two case reports in the 1990s and a 2020 case series involving 34 patients did not investigate cryotherapy as a treatment option.\textsuperscript{28,29}

Although there are various treatment options for keloids, this treatment modality should be considered as there was a complete resolution (Figure 7) of the keloid using IL cryotherapy with post-procedure IL triamcinolone acetonide and onabotulinumtoxinA injections. The patient also described no side effects during the procedure. The patient reported mild side effects post-procedure including moderate pain and hypopigmentation. This low rate of side effects supports other research showing IL cryotherapy offers less pain, blister formation, and hypopigmentation than contact cryotherapy.\textsuperscript{23} The patient’s pain post-procedure was effectively managed with codeine/acetaminophen 30 mg/300 mg. Topical formulations containing niacinamide, tranexamic acid, kojic acid, 1,4-diaminobutane dihydrochloride, and bisabolol were provided for hyperpigmentation and hypertrophic scarring; several clinical trials have supported the use of these ingredients for hypopigmentation and hypertrophic scarring as they are effective and well-tolerated.\textsuperscript{30–36} Post-procedure, IL triamcinolone acetonide and onabotulinumtoxinA injections of the treated keloid minimized the chance of recurrence. This supports other studies that have shown that IL triamcinolone acetonide injections combined with onabotulinumtoxinA injections provide scar improvement and symptomatic control on keloid recurrence.\textsuperscript{37}

However, each patient’s case must be reviewed prior to pursuing this treatment as other factors should be considered, such as cost of treatment and size of keloids as this treatment is most effective on large or pedunculated keloids. In conclusion, we encountered a pedunculated umbilical keloid that was effectively treated with IL cryotherapy followed by IL triamcinolone acetonide and onabotulinumtoxinA injections. Overall, due to the low rate of side effects, high patient satisfaction, and absence of recurrence, this treatment modality should be considered as an option for umbilical keloids.

Acknowledgements
We would like to thank our patient for their interest and permission to describe this case report. We would also like to thank Lesley Monterroso RPN for her involvement in the treatment and patient care management.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship and/or publication of this article.

ORCID iD
Jennifer VH Tran https://orcid.org/0000-0003-1529-338X

References
1. Niessen FB, Spauwen PH, Schalkwijk J, et al. On the nature of hypertrophic scars and keloids: a review. Plast Reconstr Surg 1999; 104: 1435–1458.
2. Hunasgi S, Koneru A, Vanishree M, et al. Keloid: a case report and review of pathophysiology and differences between keloid and hypertrophic scars. J Oral Maxillofac Pathol 2013; 17: 116–120.
3. Ledon JA, Savas J, Franca K, et al. Intralesional treatment for keloids and hypertrophic scars: a review. Dermatol Surg 2013; 39: 1745–1757.
4. Dohi T, Kuribayashi S, Aoki M, et al. Combination therapy composed of surgery, postoperative radiotherapy, and wound self-management for umbilical keloids. Plast Reconstr Surg Glob Open 2020; 8: e3181.
5. Gupta S and Sharma VK. Standard guidelines of care: keloids and hypertrophic scars. Indian J Dermatol Venereol Leprol 2011; 77: 94–100.
6. Goldenberg G and Luber A J. Use of intralesional cryosurgery as an innovative therapy for keloid scars and a review of current treatments. J Clin Aesthetic Dermatol 2013; 6: 23–26.
7. Defty C, Cubitt JJ and Murison MS. Can intralesional cryosurgery reshape the management of difficult keloid scars? Burns 2016; 42: 2059–2066.
8. Betarbet U and Blalock TW. Keloids: a review of etiology, prevention, and treatment. J Clin Aesthetic Dermatol 2020; 13: 33.
9. Perdanasari AT, Laizeri D, Su W, et al. Recent developments in the use of intralesional injections keloid treatment. Arch Plast Surg 2014; 41: 620–628.
10. Muneuchi G, Suzuki S, Onodera M, et al. Long-term outcome of intralesional injection of triamcinolone acetonide for the
treatment of keloid scars in Asian patients. Scand J Plast Reconstr Surg Hand Surg 2006; 40: 111–116.
11. Park TH, Seo SW, Kim JK, et al. Clinical characteristics of facial keloids treated with surgical excision followed by intra- and post-operative intraleisonal steroid injections. Aesthetic Plast Surg 2012; 36: 169–173.
12. Anthony ET, Lemonas P, Navasria HA, et al. The cost effectiveness of intralesional steroid therapy for keloids. Dermatol Surg 2010; 36: 1624–1626.
13. Juckett G and Hartman-Adams H. Management of keloids and hypertrophic scars. Am Fam Physician 2009; 80: 253–260.
14. Sohrabi C and Goutos I. The use of botulinum toxin in keloid treatment of keloids and hypertrophic scars. A prospective trial of case series. Br J Dermatol 2010; 162: 435–441.
15. Lee DH, Oh SY, Koo KT, et al. Reduction in the appearance of facial hyperpigmentation after use of moisturizers with a combination of topical niacinamide and N-acetyl glucosamine: results of a randomized, double-blind, vehicle-controlled trial. Br J Dermatol’2010; 162: 435–441.
16. Shaarawy E, Hegazy RA and Abdel Hay RM. Intraleisonal botulinum toxin type A equally effective and better tolerated than intraleisonal steroid in the treatment of keloids: a randomized controlled trial. J Cosmet Dermatol 2015; 14: 161–166.
17. Barara M, Mendiratta V and Chander R. Cryotherapy in treatment of keloids: evaluation of factors affecting treatment outcome. J Cutan Aesthet Surg 2012; 5: 185.
18. Zouboulis CC, Blume U, Büttner P, et al. Outcomes of cryosurgery in keloids and hypertrophic scars: a prospective consecutive trial of case series. Arch Dermatol 1995; 129: 1146–1151.
19. Zouboulis CC. Principles of cutaneous cryosurgery: an update. Dermatol 1999; 198: 111–117.
20. Mourad B, Elfar N and Elsheikh S. Spray versus intraleisonal cryotherapy for keloid scars: a prospective study. Plast Reconstr Surg 2015; 135: 580–589.
21. Weshahy AH and Abdel Hay R. Intraleisonal cryosurgery and intraleisonal steroid injection: a good combination therapy for treatment of keloids and hypertrophic scars. Dermatol Ther 2012; 25: 273–276.
22. Abdel-Meguid AM, Weshahy AH, Sayed DS, et al. Intraleisonal vs. Contact cryosurgery in treatment of keloids: a clinical and immunohistochemical study. Int J Dermatol 2015; 54: 468–473.
23. Expanding the involution of hypertrophic scars and keloids. Plast Reconstr Surg 2005; 111: 1841–1852.
24. Arno AJ, Gauglitz GG, Barret JP, et al. Up-to-date approach to manage keloids and hypertrophic scars: a useful guide. Burns 2014; 40: 1255–1266.
25. Lee YI, Kim J, Yang CE, et al. Combined therapeutic strategies for keloid treatment. Dermatol Surg 2019; 45: 802–810.
26. Lee YI, Kim J, Yang CE, et al. Combined therapeutic strategies for keloid treatment. Dermatol Surg 2019; 45: 802–810.
27. Brissett E and Sherris DA. Scar contractures, hypertrophic scars, and keloids. Facial Plast Surg 2001; 17: 263–272.
28. Ikard RW and Wahl RW. Umbilical stumps with keloid: South Med J 1996; 83: 1494–1495.
29. Ford T and Widerger AD. Umbilical keloid: an early start. Ann Plast Surg 1990; 25: 214–215.
30. Kimball AB, Kaczvinsky JR, Li J, et al. Reduction in the appearance of facial hyperpigmentation after use of moisturizers with a combination of topical niacinamide and tranexamic acid: a randomised, double-blind, vehicle-controlled trial. J Dermatol 2015; 42: 211–215.
31. Lee DH, Oh SY, Koo KT, et al. Reduction in the appearance of facial hyperpigmentation after treatment with a combination of topical niacinamide and tranexamic acid: a randomised, double-blind, vehicle-controlled trial. Skin Res Technol 2014; 20: 208–212.
32. Konda S, Garia A and Halder RM. New horizons in treating disorders of hyperpigmentation in skin of color. Semin Cutan Med Surg 2012; 31: 133–139.
33. Hollinger JC, Angra K and Halder RM. Are natural ingredients effective in the management of hyperpigmentation? A systematic review. J Clin Aesthetic Dermatol 2018; 11: 28.
34. Grimes PE. Management of hyperpigmentation in darker racial ethnic groups. Semin Cutan Med Surg 2009; 28: 77–85.
35. Desai S, Ayres E, Bak H, et al. Effect of a tranexamic acid, kojic acid, and niacinamide containing serum on facial dyschromia: a clinical evaluation. J Drugs Dermatol 2019; 18: 454–459.
36. Lee J, Jun H, Jung E, et al. Whitening effect of α-hydroxy acid, kojic acid, niacinamide, and tranexamic acid: a randomized, double-blind, vehicle-controlled trial. Skin Res Technol 2014; 20: 208–212.
37. Rasaii S, Sohrabian G, Gianfaldoni S, et al. Intraleisonal triamcinolone alone or in combination with botulinum toxin A is ineffective for the treatment of formed keloid scar: a double blind controlled pilot study. Dermatol Ther 2019; 32: e12781.

How to cite this article
Tran JVH, Luitchi SDJ, Supra S, Dong K, Gusic K and Goldstein M. Intraleisonal cryotherapy with triamcinolone and onobotulinumtoxinA injections for umbilical keloid: A case report. Scars, Burns, & Healing. Volume 7, 2021. DOI: 10.1177/20595131211049040.